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Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis
ABSTRACT
Introduction: Psoriatic arthritis (PsA) is a chronic inflammatory disease that can result in
significant disability. With the emergence of tumor necrosis factor inhibitors (TNFi), therapeutic
outcomes in PsA have improved substantially. The clinical efficacy and the inhibition of
radiographic progression demonstrated by TNFi have transformed the management of PsA.
However, there is still an unmet need for a subset of patients who do not respond adequately to
TNFi.
Areas Covered: This review provides an overview of the pharmacokinetics of TNFi, the efficacy
of TNFi in PsA, and the role of immunogenicity of TNFi in the treatment of PsA. In addition, we
address the use of TNFi in the setting of other medications utilized in the treatment of PsA and
the potential future role of biosimilars.
Expert Commentary: Monoclonal antibodies exhibit complex and widely variable
pharmacokinetics. The study of factors that can affect the pharmacokinetics, such as
immunogenicity, is valuable to further define and understand the use of TNFi in PsA, especially
in the subset of patients who do not respond adequately to these agents or lose effectiveness over
time.

1. Introduction
Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints, periarticular
structures, skin, and nails. The disease can result in permanent joint damage and disability. The
prevalence of PsA ranges from 0.06% to 0.25% in developed countries such as the US, UK, and
Western Europe. It is common among patients with psoriasis with a prevalence ranging from 641% [1]. Treatment of PsA has evolved substantially since the 1990s with introduction of the
tumor necrosis factor inhibitors (TNFi). This review will focus on the pharmacology and clinical
efficacy of the TNFi in PsA.
2. Psoriatic Arthritis
2.1 Clinical Manifestations
PsA is a heterogeneous condition encompassing a wide range of clinical manifestations that
include the key domains of peripheral and axial arthritis, inflammation at tendon/ligament
insertion sites (enthesitis), diffuse swelling of an entire finger or toe (dactylitis), nail disease, and
psoriasis [2]. The incidence and prevalence of cardiovascular disease and diabetes is increased
in PsA [3]. Inflammatory bowel disease and ophthalmic disease, particularly uveitis, are
considered extra-articular manifestations of the disease [3-4].
2.2 Risk Factors
Although PsA can occur prior to developing psoriasis, psoriasis usually precedes PsA in the vast
majority of patients by approximately 10 years [5-6]. Obesity has been associated with an
increased risk of developing PsA not only in patients with psoriasis, but also among patients in
the general population [7-8]. Nail disease has been suggested as a potential risk factor for PsA
but may also be just an early feature of the disease [1]. Intergluteal/perianal psoriasis, and scalp
lesions in psoriasis patients may be associated with a greater likelihood of developing PsA [9].

Other potential associations include a family history of PsA and severe psoriatic dermatoses [1011].
2.3. Importance of Early Diagnosis
Early diagnosis of PsA is crucial for prevention of disease progression [12] and may also
influence development of comorbidities. Early PsA has been defined as within one to two years
of the onset of symptoms [13]. Erosions and worse long term physical outcomes have been
demonstrated with even a six-month delay in diagnosis [14-17]. Unlike conventional synthetic
disease modifying antirheumatic drugs (csDMARDs), TNFi have been demonstrated to prevent
or slow radiographic progression of PsA. Early institution of therapy within 6 months of disease
initiation results in improved response to therapy and improved long term outcomes [12, 18].
2.4. Treatment
The most widely used consensus treatment recommendations are The Group for Research and
Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) and the European League Against
Rheumatism (EULAR) recommendations (Figure 1 & 2). Overarching principles of therapy are
similar, and include shared decision making with the patient, controlling symptoms and
preventing damage, improving quality of life, minimizing or avoiding complications, and
assessing comorbidities. A central feature in the treatment of PsA is considering all the domains
involved when deciding on a treatment regimen. The GRAPPA and EULAR recommendations
favor a “step-up” approach for the treatment of PsA [4,19]. NSAIDS and intra-articular
corticosteroids may be effective in reducing pain from inflammation. Traditional oral therapies
such as methotrexate (MTX), leflunomide (LEF), and sulfasalazine (SSZ) can decrease
inflammation and improve symptoms. Both NSAIDS and csDMARDs are commonly used in
PsA, but neither treat all domains of the disease. Other than the TICOPA study, a treat to target

study in PsA [20], there is little data confirming the efficacy of MTX in PsA [21-23]. However,
csDMARDS, particularly MTX, continue to be a mainstay of treatment even though they have
not been shown to clearly inhibit radiographic progression and there is a paucity of efficacy data.
MTX remains the most commonly used therapy for PsA and has good retention rates (e.g, 2-year
retention rates of 65%, Lie et al. in 2010 [24]). The GRAPPA recommendations do not
specifically delineate MTX as the csDMARD of choice or TNFi as the first biologic DMARD
(bDMARD) of choice [4]. TNFi are the first line bDMARD of choice in the EULAR
recommendations on the basis of clinical data and evidence of efficacy and long-term safety data
that is available compared to other biologic agents, such as the IL-17A inhibitor, secukinumab,
and the IL-12/23 inhibitor, ustekinumab [19]. Furthermore, the TNFi have been shown to inhibit
progressive joint destruction and are an effective treatment for all domains of the disease [25].
As there is a paucity of data on axial disease in PsA, recommendations are derived from data for
axial spondyloarthritis [26-30]. Both organizations recommend bDMARDs after NSAID failure
for axial disease and enthesitis as csDMARDs are not efficacious in these two disease domains
[4,19]. A distinction between the two sets of recommendations is that GRAPPA
recommendations allow for an “expedited therapeutic route” in which csDMARDs are bypassed
and a bDMARD may be initiated early. This recommendation is based on a) the efficacy of
bDMARDS and relatively little data for traditional oral agents for long term prevention of
progression and b) the relative lack of efficacy of oral agents for enthesitis, both particularly in
the patient with poor prognostic factors (e.g., elevated C-reactive protein or high joint counts)
[4].
2.4.1 Defining Treatment Response
The primary outcome used in PsA randomized controlled trials (RCTs) is the American College

of Rheumatology (ACR)-20% improvement criteria. Patients must achieve at least a 20%
improvement in the tender and swollen joint counts and at least three of the five remaining
outcome measures: Health Assessment Questionnaire-Disability Index, Patient pain assessment,
Patient global assessment, Physician global assessment, C-reactive protein. Psoriasis severity is
measured in RCTs using the Psoriasis Area and Severity Index (PASI) score. The PASI75 is an
improvement of at least 75% in the PASI score [31]. PASI75 (or even PASI90) is generally a
secondary outcome in RCTs examining therapies for PsA. While ACR20 and PASI are the most
commonly used outcome measures in trials, these measures are not often used in clinical
practice. Instead a variety of outcome measures are used including joint counts, enthesitis
measures, dactylitis assessment, psoriasis severity, and patient reported outcomes [6, 32].
3. Tumor Necrosis Factor
In 1975, TNF was recognized as an endotoxin-induced glycoprotein that caused hemorrhagic
necrosis of transplanted sarcomas in mice [33]. Since then, it has been associated with a wide
range of biologic conditions and has been identified as an important pro-inflammatory cytokine
[34]. Overexpression of TNF has been implicated in the pathogenesis of a wide variety of
diseases, such as rheumatoid arthritis, inflammatory bowel disease, psoriasis, and PsA [35-36].
TNF is a pleotropic cytokine that is produced by cells such as activated macrophages, T
lymphocytes, monocytes, neutrophils, mast cells, endothelial cells, fibroblasts, and osteoclasts.
It is a key driver of many inflammatory activities in the body and also contributes to cell
proliferation, apoptosis, and angiogenesis [35, 37]. Transmembrane TNF (tmTNF), a 26 kDa
protein, is cleaved by a metalloproteinase, TNF-alpha-converting enzyme (TACE), and is
ultimately released as a soluble cytokine, sTNF (17kDa) [34, 38-40]. sTNF and tmTNF can then
bind to TNF receptor 1 (TNFR1, p55) or TNF receptor 2 (TNFR2, p75) and exert biological

effects on various cell types [34, 38]. TNFR1 and TNFR2 use different signaling mechanisms;
they have differing affinities to ligands and distinct cellular expression profiles [38]. These
differences may contribute to varied biological responses [34, 41].
4. Role of TNF in the Pathogenesis of PsA (Figure 3)
While genetic and environmental factors may play a role in the development of PsA, the immune
response to such triggers is what sustains the disease. Inflammation in PsA is thought to be
driven both by the Th1 and Th17 pathways. In both pathways, TNF superfamily proteins
are important for sustaining inflammation [42]. When the inciting antigen is presented to the
initial T-cell, unregulated IL-12 causes differentiation and propagation of Th1 cells and
contributes to the release of pro-inflammatory cytokines, including TNF [43]. Conversely, IL-23
is thought to play a key role in the pathogenesis of PsA by triggering Th17 cell differentiation
[44]. This leads to production of IL-22 and IL-17. IL-17 leads to upregulation of TNF [45].
TNF, along with several other cytokines, induces expression of receptor activator of nuclear
factor-κB ligand (RANK-L), a member of the TNF superfamily, promoting
osteoclastogenesis and eventually erosion formation [46]. TNF also induces expression of
Dickkopf-related protein 1 (Dkk-1) by synovial fibroblasts, inhibiting osteoblastogenesis, further
promoting erosions [46].
5. TNF Inhibitors
Etanercept, infliximab, adalimumab, certolizumab pegol, and golimumab are the TNFi that have
been approved for PsA in the US and UK. Etanercept was the first FDA approved TNFi for the
treatment of PsA in January 2002.
5.1 Structure and Mechanism of Action of TNFi
TNFi are monoclonal antibody therapeutics directed at TNF. IgG monoclonal antibodies are

large proteins that possess hydrophilic properties [48]. They consist of two unique heavy chains
and two unique light chains each of which has constant and variable domains [48]. The heavy
and light chains are linked by disulfide bonds and connected by disulfide bonds at the hinge
region to a fragment crystallizable (Fc) region [49]. The fragment antigen-binding region (Fab)
is the antigen-binding portion and the Fc region is the portion which takes part in Fc mediated
actions, such as complement-dependent cytotoxicity and antibody-dependent cell mediated
cytotoxicity [50]. The Fc portion also binds to the neonatal Fc receptor (FcRn), which is
integral in protecting the antibody from intracellular catabolism [49, 51]. The hypervariable
region at the top of the variable domain is where binding to the target antigen occurs [48-49].

With the exception of certolizumab and etanercept, the remaining three TNFi are full-length
bivalent monoclonal antibodies (mAB) [38] (Figure 4). Certolizumab is a humanized (exogenic
hypervariable regions) IgG1 monoclonal antibody with a Fab1 fragment [38, 48]. The hinge
region is modified and is linked to polyethylene glycol allowing for better solubility, half-life,
bioavailability, and decreased immunogenicity. It has an affinity for both sTNF and tmTNF
[52]. Unlike the other TNFi, certolizumab does not have an Fc portion and therefore does not
take part in Fc mediated actions [50]. In contrast to the other TNFi, etanercept is a genetically
engineered soluble fusion protein that is composed of two extracellular portions of the p75 TNF
receptor linked to the Fc portion of human IgG1 [38]. It binds to both sTNF and tmTNF at the
receptor binding site, preventing the binding of TNF with the p75 receptor [38, 53]. The short
half-life of entanercept may in part be due to a difference in the conformation of the Fc region
[38]. In addition, etanercept is the only TNFi of the five that also binds members of the
lymphotoxin (LT) family (also members of the TNF superfamily), specifically LTα3 and

LTα2β1 [38]. Infliximab is unique in that it is a chimeric IgG1k mouse and human monoclonal
antibody that consists of human constant regions of IgG1k and murine variable regions [38, 54].
It binds to both sTNF and tmTNF with high affinity via the E-F loop, blocking the ability of TNF
to bind to its receptors [55]. Adalimumab is a recombinant human IgG1 antibody. It occupies
the TNF receptor-binding site of both sTNF and tmTNF with high affinity, preventing the
binding of TNF to its receptors [54-55]. Like adalimumab, golimumab is a human
immunoglobulin IgG1 monoclonal antibody that binds to both sTNF and tmTNF [38, 56].
(Table 1)
5.2 General Pharmacokinetic Properties of TNFi
5.2.1 Absorption
As large protein molecules with poor membrane permeability, TNFi are administered
parenterally. The oral bioavailability is very low as they are denatured in the acidic environment
of the stomach or they undergo a rapid proteolytic cleavage in the GI tract [49, 57]. It is
hypothesized that monoclonal antibodies are absorbed via the lymphatic system by convection
and diffusion across blood vessels [49, 51]. Absorption can take anywhere from about one to
eight days [58]. Most of the TNFi are administered subcutaneously (infliximab is intravenous
only and golimumab can be given IV or subcutaneously), which can cause variability among
patients in regards to the amount of drug absorbed [59].
5.2.2 Distribution
Given their large weight and hydrophilic nature, monoclonal antibodies usually have a small
volume of distribution [49]. The molecules usually reside in the vascular and interstitial spaces
and are distributed via paracellular movement by convection and via transcellular movement by
endocytosis (phagocytosis, receptor-mediated endocytosis, or fluid-phase pinocytosis) [49, 51].

Convective transport is driven by the blood-tissue hydrostatic pressure gradient. Osmotic
pressure gradients and the characteristics of the paracellular pores also affect convective
transport [58].
5.2.3 Metabolism and Excretion
Since monoclonal antibodies are large molecules, they are not predominantly renally excreted.
The PEG portion of certolizumab decreases its renal excretion secondary to increasing the size of
the molecule [52]. Very little is also excreted in bile [49, 51]. These molecules undergo
catabolic metabolism via Fc-receptor mediated elimination and target mediated elimination
(clearance following binding to target) [49]. The Fc portion is also thought to contribute to the
long half-life of most of these monoclonal antibodies since it interacts with the FcRn, which has
a mechanism that protects these molecules from systemic elimination [60]. (Table 2)
5.3 Pharmacokinetics of TNFi
TNFi differ in their pharmacokinetic (PK) properties. Underlying disease type or severity, body
weight, immunogenicity, and the concomitant use of other medications such as MTX can impact
PK parameters. Elimination of TNFi for the treatment of PsA generally follows linear kinetics
and volume of distribution is that of the central compartment (~6 L). [48, 61-66]. Table 3
outlines the pharmacokinetics of monoclonal antibodies utilized in rheumatic diseases with an
emphasis, when available, on population pharmacokinetic parameters in PsA.
5.3.1 Obesity
Obesity impacts the pharmacokinetics of TNFi. Higher disease activity is seen in obese PsA
patients and disease registries suggest obesity is associated with a decreased response to TNFi
[78]. PsA patients on TNFi that lost >5% from their baseline weight were found to be
significantly more likely to achieve minimal disease activity (MDA) than patients who did not

lose weight [79]. Obesity may affect the pharmacokinetics of TNFi secondary to insufficient
dosing, changes in volume of distribution, and increased drug elimination. [48, 78].
5.3.2 Immunogenicity
Immunogenicity, the ability of a substance to cause an immune response [49], can play a role in
the varying pharmacokinetics of monoclonal antibodies. The underlying disease, duration of
treatment, route of administration, concomitant medications, dose frequency, genetic
predisposition, assay methodology, and the type of antibody can all affect the immunogenicity of
TNFi [80-82]. Humanization of monoclonal antibodies may help to decrease immunogenicity
[48, 51]. Thus, the chimeric structure of infliximab can account for its high immunogenicity
potential. A meta-analysis of TNFi immunogenicity in RA, inflammatory bowel disease, and
spondyloarthritis (PsA and ankylosing spondylitis) among patients using one of the five TNFi
demonstrated infliximab was the most and etanercept the least immunogenic [83]. There is
sparse data regarding the extent of immunogenicity of golimumab and certolizumab in PsA.
The elimination rate of TNFi is impacted by immunogenicity. Anti-drug antibodies will increase
the elimination rate of TNFi [48, 67, 75, 80]. They may form immune complexes with the drug
accelerating its clearance [84]. Small studies have demonstrated a correlation between antiadalimumab antibodies and decreased serum concentration and thus decreased clinical response
[85-86]. Another small study demonstrated elevated levels of anti-drug antibodies to
adalimumab and infliximab, but not etanercept in PsA patients, which correlated with low
therapeutic drug levels and thus decreased drug efficacy [87].
5.3.3 Concomitant use of MTX and Immunogenicity
There is an association between MTX, a widely used therapy in PsA, and the development of
anti-drug antibodies. A meta-analysis by Thomas et al showed that MTX can attenuate the

formation of antibodies by 74% overall and antibodies decreased clinical response by 18%
overall in SpA (based on 4 studies looking at infliximab, adalimumab, and etanercept [83]. In
RCTs of infliximab and golimumab, a greater proportion of patients on TNFi monotherapy were
positive for antibodies compared to those taking concomitant MTX [88-89]. However, efficacy
of TNFi is not generally impacted by MTX use [88-94]. Interestingly, a post-hoc analysis
determined that patients who were taking combination MTX and golimumab had a ten percent
greater improvement in nail, dactylitis, and enthesitis scores compared to those not taking MTX
[89]. In an observational cohort study of 375 patients with RA or PsA treated with adalimumab,
trough concentrations were higher in patients concomitantly taking MTX and lower in patients
on adalimumab monotherapy [95].
6. Key Clinical Trials of TNFi in PsA
TNFi in PsA were found to be efficacious with tolerable safety profiles in pivotal phase III trials
(Table 4). The most common adverse events include injection site reactions, infusion reactions
in infliximab, and infections [6]. All five TNFi demonstrated an inhibition in radiographic
progression. In the GO-REVEAL 5-year study, concomitant MTX appeared to reduce
radiographic progression [91]. Only the certolizumab trials included patients who were exposed
to TNFi previously (19.8% of patients). Interestingly, improvements in ACR 20 response rates
at 12, 24, and 96 weeks were observed for both doses regardless of prior TNFi exposure [93, 96].
7. Other Treatment Options for PsA
A number of patients do not respond to TNFi and many more have a loss of response over time.
Thus, recognition of the IL-23/IL-17 pathway in the pathogenesis of PsA and molecules that are
targeting other cytokines in the pathway have been integral to the development of further
medications to treat PsA.

7.1 Apremilast
Apremilast is an oral phosphodiesterase 4 inhibitor (PDE-4i) that is approved for the treatment of
PsA. PDE4 mediates the breakdown of cAMP, which regulates inflammatory responses. Thus,
PDE4 inhibitors demonstrate anti-inflammatory effects [103]. The clinical efficacy of apremilast
in PsA patients who have already been treated with csDMARDS and/or bDMARDS or are on
csDMARDS was studied extensively with several pivotal randomized placebo-controlled trials
(Table 5). In the Psoriatic Arthritis Long-term Assessment of Clinical Efficacy (PALACE)
phase III trials, in PALACE 1, 2, and 3, the primary endpoint, an ACR20 response at week 16,
was achieved by significantly more patients taking apremilast 20 mg or 30 mg bid as compared
to placebo regardless of prior treatment. bDMARD-naïve patients had higher ACR20 response
rates [104-106]. Sustained improvements were seen through week 52 in PALACE 1, 2, and 3. In
PALACE 4, patients who were DMARD-naïve were studied over a 52-week period. The
primary end point was met for both doses at weeks 16 and 52 [107]. Studies suggested a lack of
efficacy of apremilast in axial disease [108-109]. The most common adverse events were
diarrhea and nausea [104-107].
7.2 Secukinumab
Secukinumab is a human IgG1 monoclonal antibody that binds to and neutralizes IL-17A.
FUTURE 1 and 2 are key phase III, randomized, double-blind, placebo-controlled trials that have
demonstrated the efficacy of secukinumab in the key domains of PsA (Table 5) [110-111].
MEASURE 1 and 2 are key phase III, randomized, double-blind, placebo-controlled trials that
have demonstrated the efficacy of secukinumab in ankylosing spondylitis and thus should be
effective for axial disease in PsA [112]. Additionally, secukinumab has been shown to decrease
radiographic progression [110]. Efficacy was noted regardless of concomitant MTX use and

among patients with prior TNF exposure, though the response was lower. Generally,
numerically higher ACR responses were noted in the anti-TNF naïve populations. Efficacy was
sustained through week 52. Candida infections were more common in secukinumab versus
placebo, which may be because IL-17 plays a role in host defense again fungal infections [110111].
7.3 Ustekinumab
Ustekinumab inhibits IL-12 and IL-23 by binding to the p40 subunit of IL-12 and IL-23.
PSUMMIT 1 and PSUMMIT 2 are pivotal phase III, double-blind, placebo-controlled trials that
studied ustekinumab in PsA patients and found that there was a significant improvement in joint
and skin disease and less radiographic progression compared to placebo (Table 5). In
PSUMMIT-1, ACR20 response rates were maintained at week 52 and efficacy was noted
regardless of MTX use [113]. In contrast to PSUMMIT-1, in PSUMMIT-2, 58% of patients had
been on TNFi previously. Clinical improvement was noted regardless of prior TNF exposure but
was again lower (as has been seen in other studies of TNF inadequate responders). Anti-TNFnaive patients appeared to have a higher clinical response than anti-TNF-experienced patients
[114]. Phase III, randomized, double-blind, placebo-controlled trials are underway to evaluate
the efficacy and safety of ustekinumab in ankylosing spondylitis [117-118]. Ustekinumab has a
tolerable safety profile with a low incidence of serious infections and sustained clinical
improvement through week 100 [115].
8. Expert Commentary
PsA is a heterogeneous, often debilitating disease that is associated with several comorbidities.
Early intervention is vital to prevent disease progression. Although csDMARDS show variable
efficacy in PsA [19,22], they have remained key medications in treatment largely in part due to

cost considerations. With the emergence of TNFi, treatment options have vastly expanded for
PsA patients. TNFi inhibit radiographic progression and are effective in treating all the domains
of PsA [25]. However, some patients do not respond to TNFi or response may wane over time.
Thus, the emergence of IL-17A inhibitors, IL-12/23 inhibitors, and small molecule treatments
such as apremilast have provided a wider range of therapeutic options for PsA. Although
apremilast has the advantage of being an oral medication with a relatively benign side effect
profile, its effect on radiographic progression has not been examined. The TNFi agents
etanercept, infliximab, adalimumab, and golimumab appear to have ACR20 advantage over
newer non-TNFi biologics such as apremilast and ustekinumab, when compared using indirect
methods [119]. There are no direct comparative efficacy trials between non-TNFi biologics,
however indirect comparisons suggest similar efficacy and safety among available agents [120].
There are also several new medications that are currently being evaluated for the treatment of
PsA (Table 6).
Even though there is an emergence of many new therapies in PsA, there is a subset of patients
that do not adequately respond to available treatments. Thus, it would be of benefit to further
study established therapies in PsA such as TNFi by assessing parameters that affect drug
concentrations in this patient population. Given that monoclonal antibodies exhibit complex and
widely variable pharmacokinetics, further population PK studies in PsA would be helpful in
identifying covariates, such as age, immunogenicity, weight, comorbidities, and concomitant
medications, which can influence dose-concentration-effect relationships [80]. Outside of
weight based dosing adjustment, individualization of dosing is currently not the standard for
monoclonal antibodies in autoimmune disease. A model based approach that links monoclonal
exposure with disease state may eventually allow for more individualized dosing based upon

disease phenotype, endotype (biomarker driven) and potentially, though less likely, genotype. In
addition to drug concentrations, anti-monoclonal drug antibody levels can play a role on the
effect of treatment discontinuation and adverse events such as infusion reactions, which have
occurred at a higher incidence in antibody positive patients [81, 88]. It can provide insight into
whether or not switching to another TNFi or a medication with a different mechanism of action
in patients with poor clinical outcomes would be of greater benefit. Thus, having a better
understanding of the factors associated with inter-individual variability and the extent of that
variability may eventually contribute to potential dosing strategies that can improve clinical
outcomes, especially in patients with TNFi failure.
While combination treatment may be common in clinical practice, there is little data regarding its
clinical efficacy [4, 19]. However, decreased immunogenicity of TNFi with concomitant MTX
may play a role in improving drug survival rates of TNFi [121-122]. In addition, one study
noted higher drug levels in a small group of 26 patients on adalimumab combination therapy
(with csDMARDS such as LEF, SSZ, or HCQ) compared to patients using adalimumab
monotherapy [95]. Prospective, randomized clinical trials of TNFi with various csDMARDs to
assess trough antibody drug concentrations, anti-drug antibody levels, the measurement of a
clinical response (ACR 20 response), and to further assess the potential long term side effects of
combination therapy in PsA would be of value.
9. Five-year View
With further understanding of the pathogenesis of PsA, novel treatment options are emerging.
Over the last several years, many effective therapeutic options have been introduced and more
are yet to come. Biosimilars, which are products similar to already approved drugs in regard to
quality, safety, and efficacy [123], may help to alleviate the economic burden associated with

TNFi. Few studies have evaluated infliximab, etanercept, and adalimumab biosimilars for PsA.
These agents have been approved in the United States for PsA based on similar efficacy to the
reference product in psoriasis and/or RA [123-124]. Immunogenicity has been the same, and in
some cases less than reference products [125]. Switching established patients in ankylosing
spondylitis and rheumatoid arthritis from infliximab to the biosimilar product CP-P13 is not
associated with a loss of control [126-127]. Extrapolation from other disease states is
complicated if alternate dosing regimens are used. RCTs or pragmatic trials specific to PsA may
provide beneficial information regarding the efficacy and safety of biosimilars, but with current
evidence the use of biosimilars in established or de novo patients appears to reasonable. Similar
to their reference products, trials evaluating how the combination of a biosimilar with a
csDMARD affects immunogenicity would be of interest. Long-term pharmacoepidemiology
studies assessing predictors of response to biosimilars and the effectiveness of switching from
the reference product to a biosimilar and vice versa will provide valuable information.
Key Issues
•

Psoriatic Arthritis is a chronic, debilitating disease associated with several comorbidities.

•

TNFi are a mainstay of treatment in PsA and inhibit radiographic progression.

•

Several factors affect the pharmacokinetic properties of TNFi, including underlying
disease type or severity, body weight, immunogenicity, and the concomitant use of other
medications such as MTX.

•

Identifying drug concentrations and anti-monoclonal drug antibody levels may help more
quickly identify patients with TNFi failure and may provide insight regarding medication
changes.

•

Assessing the effect of combination csDMARDS and TNFi on immunogenicity may

contribute to future treatment recommendations.
•

While not tested specifically in PsA, biosimilars are expected to have similar efficacy and
safety to reference products.
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FIGURES

Figure 1. Simplified GRAPPA Treatment Recommendations [4]
*combination csDMARDS and TNFi common in clinical practice
**

Conditional recommendations: At the time these recommendations were published, these drugs

were not approved or recommendations were based on data from abstracts
csDMARD, conventional synthetic DMARD; CSA, cyclosporin A; GRAPPA, Group for
Research and Assessment of Psoriasis and Psoriatic Arthritis; IL-17i, interleukin-17 inhibitor;
IL-12/23i, interleukin-12/23 inhibitor; LEF, leflunomide; MTX, methotrexate; NSAIDS,
nonsteroidal anti-inflammatory drugs; PDE-4i, phosphodiesterase 4 inhibitor; SSZ, sulfasalazine;
tsDMARD, targeted synthetic DMARD; TNFi, tumor necrosis factor inhibitor

Figure 2. Simplified EULAR Treatment Recommendations [19]

*bDMARD includes TNFi, IL-12/23i, IL-17i. The preference initially is a TNFi, but if
contraindicated, can consider one of the others or a PDE-4i.
**no adverse prognostic factors: can try a second csDMARD or combination therapy
bDMARD, biologic DMARD; csDMARD, conventional synthetic DMARD; CI,
contraindicated; EULAR, European League Against Rheumatism; IL-17i, interleukin-17
inhibitor; IL-12/23i, interleukin-12/23 inhibitor; LEF, leflunomide; MTX, methotrexate;
NSAIDS, nonsteroidal anti-inflammatory drugs; PDE-4i, phosphodiesterase 4 inhibitor; SSZ,
sulfasalazine; tsDMARD, targeted synthetic DMARD; TNFi, tumor necrosis factor inhibitor

Figure 3. Pathogenesis of Psoriatic Arthritis
The Th1 and Th17 pathways are important pathways involved in the pathogenesis of PsA. TNF,
a pro-inflammatory cytokine, is a key player in osteoclastogenesis via RANK-L and in inhibition
of osteoblastogenesis via Dkk-1. Both processes eventually lead to bone erosions [46]. In
addition, IL-22 is involved in the pathologic formation of new bone (osteoproliferation) [47].
APC, antigen presenting cell; Dkk-1, dickkopf-related protein 1; IFNγ, interferon gamma; IL-12,
interleukin-12; IL-17, interleukin-17; IL-22, interleukin-22; IL-23, interleukin-23; RANK-L,
receptor activator of nuclear factor-κB ligand; T cell, T lymphocyte; Th1, type 1 T helper cell;
Th17, T helper 17 cell; TNF, tumor necrosis factor

Figure 4. Simplified structures of TNFi
Fab, fragment antigen-binding; Fc, fragment crystallizable region; IgG1, immunoglobulin G1;
PEG, polyethylene glycol; TNF, tumor necrosis factor; TNFR2, tumor necrosis factor receptor 2

Tables

Table 1. Basic Characteristics of TNFi
TNFi

Structure

Protein Type

Affinity

Fc Portion?

Infliximab

Full length bivalent
mAb

Chimeric &
Human

sTNF & tmTNF

Yes

Genetically engineered Recombinant
Fc-fusion protein
Human

sTNF, tmTNF,
LTα3, LTα2β1

Yes

Etanercept

Adalimumab

Full length bivalent
mAb

Fully Human sTNF & tmTNF

Yes

Golimumab

Full length bivalent
mAb

Fully Human sTNF & tmTNF

Yes

Certolizumab
Pegol

Monovalent Fab1
antibody fragment

Humanized

sTNF & tmTNF

No

Fab, fragment antigen-binding; Fc, fragment crystallizable region; LTα3, lymphotoxin alpha 3;
LTα2β1, lymphotoxin alpha 2 beta 1; mAb, monoclonal antibody; sTNF, soluble tumor necrosis
factor; tmTNF, transmembrane tumor necrosis factor; TNFi, tumor necrosis factor inhibitor

Table 2. General Pharmacokinetic Properties of Monoclonal Antibodies

Absorption

Lymphatic system via convection &
diffusion

Distribution

Small volume of distribution,
paracellular and transcellular movement

Metabolism and Excretion

Catabolic metabolism

Table 3 Pharmacokinetics of TNFi in Rheumatologic Diseases
Infliximab
IV

Etanercept c
SC

Adalimumab
SC

Golimumab
SC

Certolizumab
SC

-

-

-

Maintenance
Dosages

3-5 mg/kg at 0,2,
and 6 wks
3-10 mg/kg every 48 wks

50 mg weekly

40 mg eow

50 mg once
a month

Half-life (t1/2)

8-10 days a

3-5 days

14 days

14 days d

400 mg at 0,2,
and 4 wks
200 mg eow
or 400 mg
once a month
14 days

Clearance (L/d)

0.26b

1.67

0.269

0.40d

0.408

Bioavailability

-

58%

64%

53%

80%

2.4 ± 1.5

4.7 ± 1.6

2.5

[53,65,70,72-73]

[65,70,75]

[61,76]

43-49 (after
loading dose)
[65-66]

Administration
Loading Dose

a

Cmax μg/ml

192 ± 51

References

[38,64,67-70]

b

Population PK in PsA for infliximab: The t1/2 life was 15.7 days [71]
based on 5 mg/kg IV in RA patients
c
PK of etanercept 50 mg once weekly is comparable to 25 mg twice a week SC [74]
d
Population pharmacokinetics in PsA were characterized using a 1-compartment
model. Clearance: 0.68 L/d, t1/2 life of golimumab was 12.5 days [77]
eow, every other week; SC, subcutaneous; IV, intravenous; TNFi, tumor necrosis factor
inhibitor; wk, week
b

Table 4. Pivotal Phase III Trials of TNFi in Psoriatic Arthritis

Infliximab

Etanercept

Adalimumab
Golimumab*

Reference

Study
Size
(n)

Doses (vs
Placebo)

% Achieving
ACR20 Response
(tx/placebo)
(primary endpt wk)

% Achieving
PASI75 Response
(tx/placebo)
(primary endpt wk)

Inhibition of
Radiographic
Progression

IMPACT [9798]

104

5 mg/kg IV

65.4/9.6 (16)

68/0 (16)

50 wks

IMPACT 2
[99-100]

200

5 mg/kg IV

58/11 (14)

64/2 (14)

6 months and 1 yr

12 wk study
[101]

60

25 mg SC 2x wk

73/13 (12)

26/0 (12)

Not studied

24 wk study
[94,102]
ADEPT [92]

205

25 mg SC 2x wk

59/15 (12)

-

12 months & 2 yrs

313

40 mg SC eow

58/14 (12)

-

24 wks

GO-REVEAL
[90-91]

405

50 mg/100 mg

51/45/9 (14)

40/58/3 (14)

24 wks & 256 wks

409

200 mg/400 mg

58/51.9/24.3 (12)

46.7/47.4/14 (12)

96 wks

Certolizumab** RAPID-PsA
[93,96]

ACR20, American College of Rheumatology 20% improvement criteria; endpt, endpoint; eow, every other week; IV, intravenous;
PASI75,  75% improvement in Psoriasis Area and Severity Index; SC, subcutaneous; tx, treatment; TNFi, tumor necrosis factor
inhibitor; wk, week; yrs, years
*SC dosing every 4 weeks
**200 mg SC every 2 weeks; 400 mg SC every 4 weeks

Table 5. Pivotal Phase III Trials for Other Treatment Options in Psoriatic Arthritis

Apremilast

Secukinumab

Ustekinumab3

1

Reference

Study
Size
(n)

Doses (vs Placebo)

% Achieving
ACR20 Response
(tx/placebo) (wk)

% Achieving
PASI75 Response
(tx/placebo) (wk)

Less Radiographic
Progression

Palace 1
[104]

504

30 mg bid/20 mg bid

38.1/30.4/19 (16)

21/17.6/4.6(24)

Not assessed

Palace 2
[105]

484

30 mg bid/20 mg bid

32.1/37.4/18.9 (16)

22.1/18.8/2.7 (16)

Not assessed

Palace 3
[106]

505

30 mg bid/20 mg bid

41/28/18 (16)

21/20/8 (16)

Not assessed

Palace 4
[107]

527

30 mg bid/20 mg bid

32.3/29.2/16.9 (16)

-

Not assessed

Future 1
[110]

606

75 mg1/150 mg 1

50.5/50/17.3 (24)

64.8/61.1/8.3 (24)

wk 24 and wk 52

Future 2
[111]

397

300 mg2/150 mg2/75 mg2

54/51/29/15 (24)

63/48/ 28 (not
sig)/16 (24)

Not assessed

PSummit-1
[113,115]
PSummit-2
[114,116]

615

90mg/45mg

49.5/42.4/22.8 (24)

62.4/57.2/11 (24)

wk 24 and 2 yrs

312

90mg/45mg

43.8/43.7/20.2 (24)

55.6/51.3/5 (24)

wk 24 and 1 yr

placebo or IV loading doses 10 mg/kg at baseline, week 2, and week 4 and then SC every 4 weeks
SC loading doses 300 mg, 150mg, 75 mg, or placebo once a week from baseline to week 4 and then SC every 4 weeks
3
placebo, 45 mg or 90 mg SC at baseline and 4 weeks and then every 12 weeks
ACR20, American College of Rheumatology 20% improvement criteria; bid, twice a day; IV, intravenous; PASI75,  75%
improvement in Psoriasis Area and Severity Index; SC, subcutaneous; tx, treatment; wk, week; yrs, years
2

Table 6. Medications in Development for PsA
Drug

Mechanism of Action

Current Phase in
Clinical Trials
SPIRIT-P2 Phase III
(NCT02349295)

Ixekizumab

IL-17A inhibitor

Abatacept

CTLA4-Ig

phase III
(NCT01860976)

Risankizumab

IL-23 inhibitor

phase II
(NCT02986373)

Guselkumab

IL-23 inhibitor

phase II
(NCT02319759)

Tofacitinib

Oral JAK inhibitor

phase III
(NCT01976364)

Tildrakizumab

IL-23 inhibitor

Unknown currently

CTLA4-Ig, cytotoxic T lymphocyte associated antigen-4 immunoglobulin fusion protein

